retatrutide phase 3 Lilly's triple agonist achieves 16.8% weight loss in trial Lilly orforglipron oral GLP-1 phase

AMG 133 (now known as maridebart cafraglutide) is an optimized GIPR/GLP-1R bispecific molecule engineered by conjugating a fully human monoclonal anti-human GIPR-Ab with two GLP-1 analogue agonist peptides using amino acid linkers

This means people have to remember to take it every day

Hair loss : Rapid weight loss can cause temporary hair thinning

Comparative effects of Roux-en-Y gastric bypass and sleeve gastrectomy on glucose homeostasis and incretin hormones in obese type 2 diabetic patients: a one-year prospective study

Quick Answer: GLP-1 medications may contribute to reflux-like symptoms through delayed gastric emptying, though acid reflux is not consistently reported as a primary adverse effect in clinical trials